Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday

Fortress Biotech (NASDAQ:FBIO) is projected to issue its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $26.17 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Fortress Biotech Stock Down 4.8%

FBIO opened at $2.99 on Monday. Fortress Biotech has a one year low of $1.33 and a one year high of $4.53. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.97 and a current ratio of 2.19. The stock has a market capitalization of $92.81 million, a P/E ratio of -16.61 and a beta of 1.38. The business’s 50-day simple moving average is $3.38 and its 200-day simple moving average is $3.22.

Institutional Trading of Fortress Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Opaleye Management Inc. acquired a new stake in Fortress Biotech during the 4th quarter worth approximately $3,989,000. Bridgeway Capital Management LLC acquired a new position in shares of Fortress Biotech in the fourth quarter valued at approximately $667,000. Vanguard Group Inc. increased its holdings in shares of Fortress Biotech by 11.4% in the third quarter. Vanguard Group Inc. now owns 950,327 shares of the biopharmaceutical company’s stock valued at $3,511,000 after purchasing an additional 97,405 shares during the period. Man Group plc purchased a new stake in shares of Fortress Biotech during the fourth quarter worth approximately $193,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Fortress Biotech during the fourth quarter worth approximately $180,000. 96.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

FBIO has been the topic of several research analyst reports. Zacks Research lowered Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. Wall Street Zen raised Fortress Biotech from a “hold” rating to a “buy” rating in a report on Sunday, November 23rd. Weiss Ratings restated a “sell (d+)” rating on shares of Fortress Biotech in a research report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Fortress Biotech in a report on Monday, February 23rd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Fortress Biotech presently has an average rating of “Hold” and a consensus price target of $17.00.

About Fortress Biotech

Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.